Triptorelin

DCTPepD ID  DCTPepD0001

Active Ingredients   Triptorelin

Description  A synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men. 

Synonyms  6-D-Tryptophan-LH-RH; 6-D-Tryptophanluteinizing Hormone-releasing Factor; AY-25650; CL-118,532; Detryptoreline; Decapeptyl; Arvekap; (D-Trp6)-GnRH; Triptorelina; Triptorelinum; Trelstar; Triptodur; Triptorelin

Disease  Prostate cancer

Classification

  

GnRH agonist Peptide and derivative

Structure Information


Molecular Formula  C64H82N18O13

Molecular Weight  1311.4

Active Sequence  XHWSYwLRPG

Sequence Length  10

Modification  X=Pyr, N-terminal NH2

Structure

 

Show IUPAC/InChI/SMILES

IUPAC Name  (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide

InChI  InChI=1S/C64H82N18O13/c1-34(2)23-46(56(88)75-45(13-7-21-69-64(66)67)63(95)82-22-8-14-52(82)62(94)72-31-53(65)85)76-58(90)48(25-36-28-70-42-11-5-3-9-40(36)42)78-57(89)47(24-35-15-17-39(84)18-16-35)77-61(93)51(32-83)81-59(91)49(26-37-29-71-43-12-6-4-10-41(37)43)79-60(92)50(27-38-30-68-33-73-38)80-55(87)44-19-20-54(86)74-44/h3-6,9-12,15-18,28-30,33-34,44-52,70-71,83-84H,7-8,13-14,19-27,31-32H2,1-2H3,(H2,65,85)(H,68,73)(H,72,94)(H,74,86)(H,75,88)(H,76,90)(H,77,93)(H,78,89)(H,79,92)(H,80,87)(H,81,91)(H4,66,67,69)/t44-,45-,46-,47-,48+,49-,50-,51-,52-/m0/s1

InChI_Key VXKHXGOKWPXYNA-PGBVPBMZSA-N

SMILES  CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8

External Codes


PubChem CID  25074470

DrugBank Accession Number  DB06825

NCI Thesaurus Code  C1267  

UNII  9081Y98W2V   GSRS

CAS  57773-63-4



Drug approval


Drug indication
    Triptorelin is indicated for the palliative treatment of advanced prostate cancer.

Drug Name Strength Dosage Form/Route Company Marketing Status Drug ID Approval year
Trelstar eq 3.75mg base/vial Injectable; Intramuscular Allergan Sales Llc Prescription NDA: 020715 2000
Trelstar eq 11.25mg base/vial Injectable; Intramuscular Allergan Sales Llc Prescription NDA: 021288 2001
Trelstar eq 22.5mg base/vial Injectable; Intramuscular Allergan Sales Llc Prescription NDA: 022437 2010
Triptodur Kit eq 22.5mg base/vial For Suspension, Extended Release; Intramuscular Arbor Pharms Llc Prescription NDA: 208956 2017
Decapeptyl 0.1 mg/ml Solution; Subcutaneous Ferring Inc Prescription DIN: 02389282 2012
Trelstar 3.75 mg/vial Injectable; Intramuscular Allergan Pharma Co. Prescription DIN: 02240000 2005
Trelstar 11.25 mg/vial Injectable; Intramuscular Allergan Pharma Co. Prescription DIN: 02243856 2005
Trelstar 22.5 mg/vial Injectable; Intramuscular Allergan Pharma Co. Prescription DIN: 02412322 2013

ClinicalTrials.gov Identifier Title Condition or disease Phase Purpose
NCT01020448 Prostate Cancer Antigen-3 (PCA-3) and TMPRSS2-ERG (T2-ERG) Score Changes During Initiation of Androgen Deprivation Therapy (ADT) With Triptorelin 22.5mg in Patients With Advanced Prostate Cancer (PCA): A Phase III, Single Arm Multicentre Study Prostate Cancer Phase 3 Treatment
NCT01753297 A Multicentric, Multinational (China and Russia), Randomised, Open, Controlled Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients Prostate Cancer Phase 4 Treatment
NCT01969578 A Randomized Phase II Study to Evaluate the Efficacy and Safety of Chemotherapy (CT) vs Androgen Deprivation Therapy (ADT) in Patients With Recurrent and/or Metastatic, Androgen Receptor (AR) Expressing, Salivary Gland Cancer (SGCs) Salivary Gland Cancer Phase 2 Treatment
NCT00667069 Randomized, Multicenter Study Comparing the Immediate Adjuvant Radiotherapy Associate With Hormonal Therapy of LH-RH Analogue (Decapeptyl® LP) vs Delayed Radiotherapy Until Biochemical Relapse Associated With Hormonal Therapy of LH-RH Analogue (Decapeptyl® LP) in Patients With Operable Prostate Cancer pT3 R1 pN0 or pNx at Intermediate Risk. Prostate Cancer Phase 3 Treatment
NCT00412022 Phase III Randomized Study of the Effects on Bone Mineral Density of Tamoxifen, Letrozole, and Letrozole + Zoledronic Acid as Adjuvant Treatment of Patients With Early Breast Cancer; VERSION 2 AMENDED Phase 3 Study of Triptorelin and Tamoxifen, Letrozole, or Letrozole + Zoledronic Acid in Adjuvant Treatment of Premenopausal Endocrine Responsive Breast Cancer Patients. Breast Cancer Phase 3 Treatment

    More clinical information is obtained from ClinicalTrials.gov.





DCTPep is developed by Dr.Zheng's team.